Celiac Disease

Epidemiology and Etiology

Epidemiology

• Occurs primarily in Whites of northern European descent: prevalence between 1:70 and 1:300
• More common in women
• Bimodal age distribution, but more common in childhood:
  • 8‒12 months of age
  • 3rd to 4th decades of life
• Family history is positive in 10%‒15% of patients.
• Celiac disease is associated with:
  • Down’s syndrome
  • Moderately increased risk of small bowel lymphoma

Etiology

Environmental, immunologic, and genetic factors contribute to the disease process:

• Environmental 
  • Triggered by gliadin, which is a component of gluten (found in wheat, barley, and rye)
  • The only autoimmune disease in which the antigen is known
• Immunologic
  • Involves both innate and adaptive immune response (type 4 hypersensitivity reaction)
  • Autoantibodies: 
    • Immunoglobulin A (IgA) anti-tissue transglutaminase 
    • Anti-endomysial
    • Anti-deamidated gliadin peptide
• Genetics: associated with HLA-DQ2 and HLA-DQ8

Pathophysiology

Gluten peptides trigger the innate immune response in intestinal epithelial cells, leading to T cell–mediated mucosal damage of the proximal small intestine (distal duodenum and proximal jejunum).

1. Presence of gliadin → release of tissue transglutaminase (tTG) (intracellular enzyme) → deaminated gliadin
2. Antigen-presenting cells process and present this to T cells → T helper cell and plasma cell activation
3. Plasma cells release anti-tTG, anti-endomysial, and anti-deamidated gliadin antibodies.
4. T helper cells → cytokine release → intraepithelial lymphocytosis and activation of fibroblasts → matrix proteases → intestinal destruction, including loss of the brush border, crypt hyperplasia, and villous atrophy 
5. This process causes impaired absorption of fat, fat-soluble vitamins, and minerals → malabsorption

Clinical Presentation

Clinical manifestations

Celiac disease may present in infancy or in the 3rd to 4th decades of life.

• Gastrointestinal (GI) symptoms:
  • Diarrhea (most common symptom)
  • Steatorrhea (bulky, foul-smelling, floating stool)
  • Bloating and flatulence
  • Abdominal cramping
• Extraintestinal manifestations:
  • Weight loss and muscle wasting
  • Fatigue and weakness
  • Failure to thrive in infants and children
  • Anemia → impaired iron and folate absorption
  • Bleeding diathesis → impaired fat-soluble vitamins → prothrombin deficiency
  • Osteopenia → defective calcium transport and vitamin D deficiency
  • Motor weakness, paresthesias, sensory loss → hypocalcemia and vitamin deficiencies
  • Dermatitis herpetiformis (pruritic papules, vesicles, and bullae on the extensor surface of extremities)
  • Peripheral edema → impaired amino acid absorption
  • Amenorrhea, delayed menarche, and infertility

Associated conditions

Celiac disease is also associated with:

• Diabetes mellitus
• Selective immunoglobulin A (IgA) deficiency
• Autoimmune thyroid diseases
• Gastroesophageal reflux disease
• Inflammatory bowel disease and microscopic colitis
• Autoimmune myocarditis
• Idiopathic dilated cardiomyopathy

Management and Prognosis

Management

• Education about the disease
• Life-long gluten-free diet
  • Consultation with a dietitian
  • Avoid barley, rye, and wheat.
  • Many will have a secondary lactose intolerance.
  • Approximately 70% of patients will have clinical improvement within 2 weeks.
• Monitoring:
  • Repeat IgA anti-tissue transglutaminase antibody at 6 and 12 months after diagnosis.
  • Small bowel biopsy after 3–6 months on a gluten-free diet
• Identify and treat any nutritional deficiencies (vitamin and mineral supplements, as needed).
• Most common reason for treatment failure is incomplete removal of gluten from the diet.
• Refractory disease:
  • 5% of patients may not respond to a gluten-free diet.
  • Consider an alternative or concurrent disease:
    • Irritable bowel syndrome
    • Small bowel bacterial overgrowth
    • Pancreatic insufficiency
    • Microscopic colitis
  • Glucocorticoids and immunosuppressants may be considered.

Prognosis

• Excellent prognosis for those who respond to treatment
• Complications associated with increased mortality:
  • Increased risk of lymphoma and GI cancer 
    • 6%–8% of patients
    • Manifests after 20–40 years with the disease
  • Collagenous sprue
    • Refractory disease with subepithelial collagen deposition
    • Leads to severe malabsorption
  • Ulcerative jejunitis
    • Aberrant T cell monoclonality causing multiple, chronic ulcers in the jejunum
    • Can lead to intestinal obstruction due to strictures

Differential Diagnosis

• Irritable bowel syndrome (IBS): a functional bowel disease presenting with recurrent abdominal pain and altered bowel habits. Irritable bowel syndrome is a diagnosis of exclusion, and celiac disease should be ruled out with a negative IgA tissue transglutaminase. Treatment includes reassurance, dietary modifications, and symptom-control measures.
• Inflammatory bowel disease (IBD): includes Crohn’s disease and ulcerative colitis, and is characterized by chronic inflammation of the GI tract due to a cell-mediated immune response to the GI mucosa. Symptoms include diarrhea, abdominal pain, weight loss, and extraintestinal manifestations. Diagnosis includes imaging, endoscopy, and biopsy. Celiac antibody serology will be negative. Treatment involves steroids, aminosalicylates, immunomodulators, and biologic agents.
• Chronic pancreatitis: persistent inflammation, fibrosis, and irreversible cell damage to the pancreas. Alcohol and biliary obstruction are common causes. Patients may have steatorrhea, abdominal pain, and other malabsorption symptoms. Imaging will show an atrophic pancreas, dilated ducts, and calcifications. Celiac disease antibody testing will be negative. Therapy includes alcohol cessation, diet changes, pain control, and treatment of pancreatic insufficiency.
• Lactose intolerance: an intolerance to lactose-containing foods due to lactase deficiency. Symptoms include crampy abdominal pain, bloating, nausea, and diarrhea. Diagnosis is based on the association with lactose-containing foods and a lactose hydrogen breath test. Management includes restriction of dietary lactose and enzyme replacement. It is common for patients with celiac disease to also have concurrent lactose intolerance.
• Small intestinal bacterial overgrowth: defined as excessive bacteria growing in the small intestine, and can result due to alteration in the intestinal anatomy or motility. Symptoms can range from mildly symptomatic to chronic diarrhea, weight loss, and malabsorption. Bacterial cultures and breath tests can distinguish this condition from celiac disease. Treatment includes antibiotics and correction of nutritional deficiencies.
• Microscopic colitis: a chronic inflammatory disease of the colon; can be categorized as collagenous or lymphocytic colitis. Patients tend to be middle-aged with chronic, watery diarrhea; abdominal pain; and bloating. A colonoscopy will appear normal, but inflammatory cells, cryptitis, or a subepithelial collagen band will be seen on biopsy, differentiating the condition from celiac disease. Treatment includes trigger avoidance, glucocorticoids, and symptom management.